Search results
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune via Yahoo Finance· 7 days agoIn the first quarter of the year, Moderna reported $167 million in sales of its only product on the...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga via Yahoo Finance· 7 days agoThursday, Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an...
Moderna COVID vaccine sales plummet 91 percent - The Boston Globe
The Boston Globe· 7 days agoSales of Moderna’s COVID-19 vaccine plunged 91 percent from the previous year for the first quarter...
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Investor's Business Daily· 21 hours agoNeither metric lines up with investing advice...stocks with recent earnings and sales growth of 20%...
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Reuters· 7 days ago, opens new tab said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC)...
Decoding Moderna Inc (MRNA): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 5 days agoStrengths Robust mRNA Technology Platform: Moderna Inc (NASDAQ:MRNA) has established a strong...
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Russell Investments Group Ltd.
ETF DAILY NEWS· 8 hours agoRussell Investments Group Ltd. cut its holdings in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 28.3% during the 4th quarter, according to its most recent Form 13F ...
Why Moderna Stock Blasted 13% Higher Today
Motley Fool via Yahoo Finance· 7 days agoModerna (NASDAQ: MRNA) was a fine stock to heal an ailing portfolio on the second-to-last trading day of the week. The company, which developed and sells...
Merit Financial Group LLC Lowers Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)
ETF DAILY NEWS· 6 hours agoMerit Financial Group LLC lowered its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 19.1% in the 4th quarter, according to its most recent 13F ...
Moderna reports $1.2bn net loss in Q1 2024
Pharmaceutical Technology via Yahoo Finance· 6 days agoThis downturn aligns with the expected transition to a seasonal market for Covid-19 vaccines. During Q1 2023, Moderna